
|Articles|October 27, 2008
Oculus imaging device approved by FDA
The PARK 1 (Pachymeter/Autorefractor/Keratometer) imaging device (Oculus) has received premarket approval from the FDA.
Advertisement
The PARK 1 (Pachymeter/Autorefractor/Keratometer) imaging device (Oculus) has received premarket approval from the FDA.
The slim, ergonomically-designed device features a 5.7" LCD display, and comprises an autorefractor combined with a Scheimpflug based non-contact pachymeter, to photograph and measure corneal thickness and lens refractive power. It can be set to PARK, ARK or P measurement modes.
The PARK 1 will be launched officially at this year's American Academy of Ophthalmology (AAO) meeting, which is to be held on November 8–11 in Atlanta, GA, US.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
BL1332 misses primary end point in phase 2 post-PRK ocular pain study
2
FLORetina-ICOOR 2026: AI moves from the image to the trial, the clinic, and the operating room
3
Water-soluble CBD eye drops lower IOP and dampen corneal sensitivity in glaucoma mouse model
4
Q&A: GLP-1 RAs and NAION, the case for a baseline exam
5











